Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļVALN
āļāļ·āđāļāļāļĢāļīāļĐāļąāļValneva SE
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJun 28, 2007
āļāļĩāļāļĩāđāļLingelbach (Thomas)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ- -
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒDepository Receipt
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJun 28
āļāļĩāđāļāļĒāļđāđ6, Rue Alain Bombard
āđāļĄāļ·āļāļSAINT-HERBLAIN
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻFrance
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ44800
āđāļāļĢāļĻāļąāļāļāđ33228073710
āđāļ§āđāļāđāļāļāđhttps://valneva.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļVALN
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJun 28, 2007
āļāļĩāļāļĩāđāļLingelbach (Thomas)
Dr. Hanneke Schuitemaker
Chief Scientific Officer
Ms. Dipal Patel
Chief Commercial Officer
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
Dr. Kathrin U. Jansen, Ph.D.
Dr. Kathrin U. Jansen, Ph.D.
Director
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
Ms. Daniele Guyot-Caparros
Ms. Daniele Guyot-Caparros
Independent Director
Mr. James Connolly
Independent Director
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Peter Buehler
Chief Financial Officer
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Hanneke Schuitemaker
Chief Scientific Officer
Ms. Dipal Patel
Chief Commercial Officer
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
Dr. Kathrin U. Jansen, Ph.D.
Dr. Kathrin U. Jansen, Ph.D.
Director
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ